
011
Strategic
report
Corporate
governance
Financial
statements
HeiQ PLC
Annual Report and Accounts 2022
The macro picture and
FY 2022 performance
FY 2022 was a challenging year
for our industry and our business,
as we faced sudden and dramatic
market disruptions in H2, caused
by large inventory de-stocking by
brands and retailers following
reduced consumer demand,
high inflation, and rising interest
rates globally. These factors were
exacerbated by the war in Ukraine
and the resulting energy crisis in
Europe has hamstrung the entire
European chemical industry. Our
business was further exposed to
prolonged COVID-19 restrictions in
China in H1, and the downturn was
protracted by a sectoral recession
in our customer segment following
the lifting of restrictions and
value chain shifts by US brands
and retailers out of China. Given
that we were investing in scaling
up our four ventures with game-
changing innovation technologies,
the sudden decrease in sales and
the related innovation financing by
the profits from our commercial
businesses not only impacted top
line performance, but also Group
profitability.
The dramatic disruption in market
demand across our value chains
also impaired the ability of our
recently acquired businesses to
achieve their business plans. The
Directors therefore have concluded
that an impairment of goodwill
recognized upon acquisition of
some of these businesses is
appropriate.
Further, we had to partly defer
revenues (and corresponding
profits) in respect of certain
partnership agreements originally
recognized in H1 2022 and H2
2022 to future periods. Previously,
we had recognized revenue from
these contracts at the point in
time of achieving certain technical
development milestones. However,
upon further review, we concluded
that it is appropriate to recognize
such revenues over time to
coincide with specific exclusivity
rights being granted by HeiQ to
the partners. Consequently, total
revenue of US$4.0 million has
been deferred over a period of four
years with initial revenues being
recognized in H2 2022.
Total revenue for the year
amounts to US$47.2 million
(2021
R
: US$55.4 million) and the
operating loss for the year was
US$-29.2 million (2021
R
: US$-1.4
million) after goodwill impairments
(aggregated goodwill impairments
in 2021 and 2022 amount to
US$13 million). The cash balance
as of December 31, 2022 was
US$8.5 million.
2023 Trading Update
Since the start of 2023, we have
taken focused steps to reduce
our cost base and reorganize the
business. We have not seen the
challenges abate in 2023 but
actions taken since the start of the
year mean we are to be in a better
position going forward to manage
the challenging macro-economic
environment, continue building
value in our core innovations and
preserve our ability to deliver when
the market demand turns.
I am pleased to report that
the initiatives set out below
have delivered an annualized
15% reduction in overheads,
becoming effective mainly from
H2 2023 onwards. As set out in
our separately reported interim
results, for H1 2023, we achieved
sales of US$20.5 million (H1
2022
R
: US$27.6 million) with a
slight decrease in margins in a
buyers-market driven by current
overcapacity (H1 2023:40.9%
vs. 41.5% for FY 2022). I want
to point out that while we have
curtailed our investments in our
four ventures, we have maintained
their value creating momentum
and thus face the corresponding
costs. The benefits of the reduced
cost base will only be felt in H2
2023, so our operating loss
for H1 2023 amounts to US$-
6.0 million (H1 2022
R
: US$-1.6
million). The cash balance as of
June 30, 2023 amounts to US$7.3
million. Our credit facilities have
historically and continue to be
uncommitted in nature, which
casts a material uncertainty on the
going concern assessment until
appropriate longer-term funding
is in place, as disclosed in the
Notes to the financial statements.
However, the Board considers
that the Group has adequate
resources and accordingly, the
financial statements continue to
be prepared on the going concern
basis. The Board is in discussions
with financial institutions to replace
the currently uncommitted credit
facilities by committed, long-term
facilities, but the outcome of these
discussions cannot be guaranteed.
Reorganizing, right-sizing
and re-focusing
At the beginning of the year we
reorganized our activities into
three commercial business
units and one “Other” segment
encompassing four innovation
ventures with no commercial
activities yet, Innovation Services
provided internally and externally
to a broad range of customers,
as well as group functions. The
three distinct business units each
have their dedicated team leader,
management team, and P&L
responsibility:
• Textiles & Flooring, under the
leadership of Mr. Mike Abbott,
headquartered out of the US
• Antimicrobials, led by Mr. Tom
Ellefsen, headquartered out of
Thailand
• Life Sciences, led by Dr. Robin
Temmerman, headquartered out
of Belgium
I will give you an update for each
of these shortly, but before I do
so, it is worth touching on how
we have built resilience into the
service offerings - Innovation,
Differentiation and Regulatory -
which are delivered through each
business unit as well as internal
services like Finance.
Besides streamlining and relocating
various support functions out of
Switzerland to lower-cost locations,
we have created clear goals and
responsibilities for all our business
and service organizations to
optimize operations and to focus
resource allocation rigorously. In
Innovation, we have focused our
R&D investment on innovation
technologies which are closest to
cash-flow generation or are already
being financed by brand partners
or through grants. In Differentiation
we are leveraging our brand
customers to promote HeiQ to
a broader (consumer) audience
thereby reducing our costs. We
have expanded our internal service
organization particularly in Finance
by implementing a centralized
accounting function and will
continue to do so to strengthen our
financial reporting processes.